BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bashiardes S, Shapiro H, Rozin S, Shibolet O, Elinav E. Non-alcoholic fatty liver and the gut microbiota. Mol Metab. 2016;5:782-794. [PMID: 27617201 DOI: 10.1016/j.molmet.2016.06.003] [Cited by in Crossref: 121] [Cited by in F6Publishing: 109] [Article Influence: 20.2] [Reference Citation Analysis]
Number Citing Articles
1 Yim JY, Kim J, Kim D, Ahmed A. Serum testosterone and non-alcoholic fatty liver disease in men and women in the US. Liver Int 2018;38:2051-9. [DOI: 10.1111/liv.13735] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
2 Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908-922. [PMID: 29967350 DOI: 10.1038/s41591-018-0104-9] [Cited by in Crossref: 777] [Cited by in F6Publishing: 742] [Article Influence: 194.3] [Reference Citation Analysis]
3 Doulberis M, Kotronis G, Gialamprinou D, Kountouras J, Katsinelos P. Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. Metabolism 2017;71:182-97. [DOI: 10.1016/j.metabol.2017.03.013] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 13.4] [Reference Citation Analysis]
4 Tsai YL, Lin TL, Chang CJ, Wu TR, Lai WF, Lu CC, Lai HC. Probiotics, prebiotics and amelioration of diseases. J Biomed Sci 2019;26:3. [PMID: 30609922 DOI: 10.1186/s12929-018-0493-6] [Cited by in Crossref: 76] [Cited by in F6Publishing: 63] [Article Influence: 25.3] [Reference Citation Analysis]
5 Li X, Wang Y, Xing Y, Xing R, Liu Y, Xu Y. Changes of gut microbiota during silybin-mediated treatment of high-fat diet-induced non-alcoholic fatty liver disease in mice. Hepatol Res 2020;50:5-14. [PMID: 31661720 DOI: 10.1111/hepr.13444] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
6 Panasevich MR, Peppler WT, Oerther DB, Wright DC, Rector RS. Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification. Physiol Genomics. 2017;49:385-399. [PMID: 28600319 DOI: 10.1152/physiolgenomics.00012.2017] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
7 Santiago-Rodriguez TM, Toranzos GA. On Controls in Ancient Microbiome Studies, and Microbial Resilience in Ancient Samples. Genes (Basel) 2018;9:E471. [PMID: 30262781 DOI: 10.3390/genes9100471] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Zhang Q, Zhang XF, Niu CY. Application prospects of glucagon-like peptide-1 receptor agonists in treatment of metabolic diseases. Shijie Huaren Xiaohua Zazhi 2020; 28(11): 393-400 [DOI: 10.11569/wcjd.v28.i11.393] [Reference Citation Analysis]
9 Wang Z, Zeng M, Wang Z, Qin F, Chen J, He Z. Dietary Polyphenols to Combat Nonalcoholic Fatty Liver Disease via the Gut-Brain-Liver Axis: A Review of Possible Mechanisms. J Agric Food Chem 2021;69:3585-600. [PMID: 33729777 DOI: 10.1021/acs.jafc.1c00751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Lau LHS, Wong SH. Microbiota, Obesity and NAFLD. Adv Exp Med Biol. 2018;1061:111-125. [PMID: 29956210 DOI: 10.1007/978-981-10-8684-7_9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
11 Fisher BS, Green RR, Brown RR, Wood MP, Hensley-McBain T, Fisher C, Chang J, Miller AD, Bosche WJ, Lifson JD, Mavigner M, Miller CJ, Gale M Jr, Silvestri G, Chahroudi A, Klatt NR, Sodora DL. Liver macrophage-associated inflammation correlates with SIV burden and is substantially reduced following cART. PLoS Pathog 2018;14:e1006871. [PMID: 29466439 DOI: 10.1371/journal.ppat.1006871] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
12 Altamirano-barrera A, Uribe M, Chávez-tapia NC, Nuño-lámbarri N. The role of the gut microbiota in the pathology and prevention of liver disease. The Journal of Nutritional Biochemistry 2018;60:1-8. [DOI: 10.1016/j.jnutbio.2018.03.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
13 Tang W, Yao X, Xia F, Yang M, Chen Z, Zhou B, Liu Q. Modulation of the Gut Microbiota in Rats by Hugan Qingzhi Tablets during the Treatment of High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease. Oxid Med Cell Longev 2018;2018:7261619. [PMID: 30671174 DOI: 10.1155/2018/7261619] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 9.3] [Reference Citation Analysis]
14 Carbajo-Pescador S, Porras D, García-Mediavilla MV, Martínez-Flórez S, Juarez-Fernández M, Cuevas MJ, Mauriz JL, González-Gallego J, Nistal E, Sánchez-Campos S. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an in vivo model of early obesity and non-alcoholic fatty liver disease. Dis Model Mech 2019;12:dmm039206. [PMID: 30971408 DOI: 10.1242/dmm.039206] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
15 Ampuero J, Sánchez-torrijos Y, Aguilera V, Bellido F, Romero-gómez M. Nuevas perspectivas terapéuticas en la esteatohepatitis no alcohólica. Gastroenterología y Hepatología 2018;41:128-42. [DOI: 10.1016/j.gastrohep.2017.07.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 de Conti A, Tryndyak V, Willett RA, Borowa-Mazgaj B, Watson A, Patton R, Khare S, Muskhelishvili L, Olson GR, Avigan MI, Cerniglia CE, Ross SA, Sanyal AJ, Beland FA, Rusyn I, Pogribny IP. Characterization of the variability in the extent of nonalcoholic fatty liver induced by a high-fat diet in the genetically diverse Collaborative Cross mouse model. FASEB J 2020;34:7773-85. [PMID: 32304142 DOI: 10.1096/fj.202000194R] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Koopman N, Molinaro A, Nieuwdorp M, Holleboom AG. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2019;50:628-639. [PMID: 31373710 DOI: 10.1111/apt.15416] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
18 Klüber P, Meurer SK, Lambertz J, Schwarz R, Zechel-Gran S, Braunschweig T, Hurka S, Domann E, Weiskirchen R. Depletion of Lipocalin 2 (LCN2) in Mice Leads to Dysbiosis and Persistent Colonization with Segmented Filamentous Bacteria. Int J Mol Sci 2021;22:13156. [PMID: 34884961 DOI: 10.3390/ijms222313156] [Reference Citation Analysis]
19 Jia Q, Li H, Zhou H, Zhang X, Zhang A, Xie Y, Li Y, Lv S, Zhang J. Role and Effective Therapeutic Target of Gut Microbiota in Heart Failure. Cardiovasc Ther 2019;2019:5164298. [PMID: 31819762 DOI: 10.1155/2019/5164298] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
20 Arab JP, Martin-Mateos RM, Shah VH. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. Hepatol Int. 2018;12:24-33. [PMID: 28550391 DOI: 10.1007/s12072-017-9798-x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 11.6] [Reference Citation Analysis]
21 Delzenne NM, Knudsen C, Beaumont M, Rodriguez J, Neyrinck AM, Bindels LB. Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut–liver axis. Proc Nutr Soc 2019;78:319-28. [DOI: 10.1017/s0029665118002756] [Cited by in Crossref: 35] [Cited by in F6Publishing: 18] [Article Influence: 11.7] [Reference Citation Analysis]
22 Chi ZC. Pathogenesis of non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2017; 25(8): 670-683 [DOI: 10.11569/wcjd.v25.i8.670] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
23 Jiang Y, Han T, Zhang ZG, Li M, Qi FX, Zhang Y, Ji YL. Potential role of thymosin beta 4 in the treatment of nonalcoholic fatty liver disease. Chronic Dis Transl Med 2017;3:165-8. [PMID: 29063072 DOI: 10.1016/j.cdtm.2017.06.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
24 Chen Y, Lin Y, Lin J, Yang N, Chen M. Sugary Kefir Strain Lactobacillus mali APS1 Ameliorated Hepatic Steatosis by Regulation of SIRT-1/Nrf-2 and Gut Microbiota in Rats. Mol Nutr Food Res 2018;62:1700903. [DOI: 10.1002/mnfr.201700903] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
25 Boeckmans J, Natale A, Buyl K, Rogiers V, De Kock J, Vanhaecke T, Rodrigues RM. Human-based systems: Mechanistic NASH modelling just around the corner? Pharmacol Res 2018;134:257-67. [PMID: 29964161 DOI: 10.1016/j.phrs.2018.06.029] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
26 Chow MD, Lee YH, Guo GL. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Mol Aspects Med. 2017;56:34-44. [PMID: 28442273 DOI: 10.1016/j.mam.2017.04.004] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 10.6] [Reference Citation Analysis]
27 Barretto SA, Lasserre F, Huillet M, Régnier M, Polizzi A, Lippi Y, Fougerat A, Person E, Bruel S, Bétoulières C, Naylies C, Lukowicz C, Smati S, Guzylack L, Olier M, Théodorou V, Mselli-Lakhal L, Zalko D, Wahli W, Loiseau N, Gamet-Payrastre L, Guillou H, Ellero-Simatos S. The pregnane X receptor drives sexually dimorphic hepatic changes in lipid and xenobiotic metabolism in response to gut microbiota in mice. Microbiome 2021;9:93. [PMID: 33879258 DOI: 10.1186/s40168-021-01050-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Deng YD, Peng XB, Zhao RR, Ma CQ, Li JN, Yao LQ. The intestinal microbial community dissimilarity in hepatitis B virus-related liver cirrhosis patients with and without at alcohol consumption. Gut Pathog. 2019;11:58. [PMID: 31788031 DOI: 10.1186/s13099-019-0337-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
29 Sutti S, Albano E. Adaptive immunity: an emerging player in the progression of NAFLD. Nat Rev Gastroenterol Hepatol 2020;17:81-92. [PMID: 31605031 DOI: 10.1038/s41575-019-0210-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 17.0] [Reference Citation Analysis]
30 Tang C, Lu Z. Health promoting activities of probiotics. J Food Biochem 2019;43:e12944. [PMID: 31368544 DOI: 10.1111/jfbc.12944] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
31 Chen G, Xie M, Wan P, Chen D, Dai Z, Ye H, Hu B, Zeng X, Liu Z. Fuzhuan Brick Tea Polysaccharides Attenuate Metabolic Syndrome in High-Fat Diet Induced Mice in Association with Modulation in the Gut Microbiota. J Agric Food Chem 2018;66:2783-95. [DOI: 10.1021/acs.jafc.8b00296] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 18.0] [Reference Citation Analysis]
32 Chen EB, Cason C, Gilbert JA, Ho KJ. Current State of Knowledge on Implications of Gut Microbiome for Surgical Conditions. J Gastrointest Surg 2018;22:1112-23. [PMID: 29623674 DOI: 10.1007/s11605-018-3755-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
33 Li F, Sun G, Wang Z, Wu W, Guo H, Peng L, Wu L, Guo X, Yang Y. Characteristics of fecal microbiota in non-alcoholic fatty liver disease patients. Sci China Life Sci 2018;61:770-8. [PMID: 29948900 DOI: 10.1007/s11427-017-9303-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
34 Kim S, Lee Y, Kim Y, Seo Y, Lee H, Ha J, Lee J, Choi Y, Oh H, Yoon Y. Akkermansia muciniphila Prevents Fatty Liver Disease, Decreases Serum Triglycerides, and Maintains Gut Homeostasis. Appl Environ Microbiol 2020;86:e03004-19. [PMID: 31953338 DOI: 10.1128/AEM.03004-19] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
35 Bao L, Yin J, Gao W, Wang Q, Yao W, Gao X. A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway. Br J Pharmacol. 2018;175:3379-3393. [PMID: 29859019 DOI: 10.1111/bph.14383] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
36 Aron-wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020;17:279-97. [DOI: 10.1038/s41575-020-0269-9] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 51.5] [Reference Citation Analysis]
37 Tang R, Jiang Y, Tan A, Ye J, Xian X, Xie Y, Wang Q, Yao Z, Mo Z. 16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones. Urolithiasis 2018;46:503-14. [PMID: 29353409 DOI: 10.1007/s00240-018-1037-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 12.5] [Reference Citation Analysis]
38 Park WJ, Song JH, Kim GT, Park TS. Ceramide and Sphingosine 1-Phosphate in Liver Diseases. Mol Cells. 2020;43:419-430. [PMID: 32392908 DOI: 10.14348/molcells.2020.0054] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
39 Maiwall R, Gupta M. Peri-transplant renal dysfunction in patients with non-alcoholic steatohepatitis undergoing liver transplantation. Transl Gastroenterol Hepatol 2020;5:18. [PMID: 32258522 DOI: 10.21037/tgh.2019.10.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Rau M, Rehman A, Dittrich M, Groen AK, Hermanns HM, Seyfried F, Beyersdorf N, Dandekar T, Rosenstiel P, Geier A. Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease. United European Gastroenterol J. 2018;6:1496-1507. [PMID: 30574320 DOI: 10.1177/2050640618804444] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 13.5] [Reference Citation Analysis]
41 Chen K, Nakasone Y, Xie K, Sakao K, Hou DX. Modulation of Allicin-Free Garlic on Gut Microbiome. Molecules 2020;25:E682. [PMID: 32033507 DOI: 10.3390/molecules25030682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Mukherji A, Dachraoui M, Baumert TF. Perturbation of the circadian clock and pathogenesis of NAFLD. Metabolism 2020;111S:154337. [PMID: 32795560 DOI: 10.1016/j.metabol.2020.154337] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
43 Boeckmans J, Natale A, Rombaut M, Buyl K, Rogiers V, De Kock J, Vanhaecke T, M Rodrigues R. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism. Cells 2019;9:E37. [PMID: 31877771 DOI: 10.3390/cells9010037] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
44 Srivastava S, Singh A, Sandeep K, Yadav D. Epigenetic Regulation of Gut Microbial Dysbiosis. Indian J Microbiol 2021;:1-5. [PMID: 33612870 DOI: 10.1007/s12088-021-00920-y] [Reference Citation Analysis]
45 Dubey RK, Tripathi V, Prabha R, Chaurasia R, Singh DP, Rao CS, El-keblawy A, Abhilash PC. Metatranscriptomics and Metaproteomics for Microbial Communities Profiling. Unravelling the Soil Microbiome. Cham: Springer International Publishing; 2020. pp. 51-60. [DOI: 10.1007/978-3-030-15516-2_5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Zhang P, Wang W, Mao M, Gao R, Shi W, Li D, Calderone R, Sui B, Tian X, Meng X. Similarities and Differences: A Comparative Review of the Molecular Mechanisms and Effectors of NAFLD and AFLD. Front Physiol 2021;12:710285. [PMID: 34393826 DOI: 10.3389/fphys.2021.710285] [Reference Citation Analysis]
47 Mohamad Nor MH, Ayob N, Mokhtar NM, Raja Ali RA, Tan GC, Wong Z, Shafiee NH, Wong YP, Mustangin M, Nawawi KNM. The Effect of Probiotics (MCP® BCMC® Strains) on Hepatic Steatosis, Small Intestinal Mucosal Immune Function, and Intestinal Barrier in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients 2021;13:3192. [PMID: 34579068 DOI: 10.3390/nu13093192] [Reference Citation Analysis]
48 Matsui M, Fukunishi S, Nakano T, Ueno T, Higuchi K, Asai A. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice. mBio 2021;12:e0115521. [PMID: 34225483 DOI: 10.1128/mBio.01155-21] [Reference Citation Analysis]
49 Jiang X, Zheng J, Zhang S, Wang B, Wu C, Guo X. Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD. Front Med (Lausanne) 2020;7:361. [PMID: 32850884 DOI: 10.3389/fmed.2020.00361] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
50 Ren Y, Geng Y, Chen H, Lu Z, Shi J, Xu Z. Polysaccharide peptides from Coriolus versicolor: A multi-targeted approach for the protection or prevention of alcoholic liver disease. Journal of Functional Foods 2018;40:769-77. [DOI: 10.1016/j.jff.2017.11.051] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
51 Wu J, Wu D, Ma K, Wang T, Shi G, Shao J, Wang C, Yan G. Paeonol ameliorates murine alcohol liver disease via mycobiota-mediated Dectin-1/IL-1β signaling pathway. J Leukoc Biol 2020;108:199-214. [PMID: 32129526 DOI: 10.1002/JLB.3MA0120-325RR] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
52 Ma J, Zhou Q, Li H. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy. Nutrients. 2017;9. [PMID: 29035308 DOI: 10.3390/nu9101124] [Cited by in Crossref: 80] [Cited by in F6Publishing: 77] [Article Influence: 16.0] [Reference Citation Analysis]
53 Klaunig JE, Li X, Wang Z. Role of xenobiotics in the induction and progression of fatty liver disease. Toxicol Res (Camb) 2018;7:664-80. [PMID: 30090613 DOI: 10.1039/c7tx00326a] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
54 Federico A, Dallio M, Caprio GG, Gravina AG, Picascia D, Masarone M, Persico M, Loguercio C. Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis. Nutrients 2017;9:E1074. [PMID: 28956816 DOI: 10.3390/nu9101074] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
55 Xue C, Li Y, Lv H, Zhang L, Bi C, Dong N, Shan A, Wang J. Oleanolic Acid Targets the Gut-Liver Axis to Alleviate Metabolic Disorders and Hepatic Steatosis. J Agric Food Chem 2021;69:7884-97. [PMID: 34251802 DOI: 10.1021/acs.jafc.1c02257] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
56 Targher G, Byrne CD. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. Nat Rev Nephrol. 2017;13:297-310. [PMID: 28218263 DOI: 10.1038/nrneph.2017.16] [Cited by in Crossref: 115] [Cited by in F6Publishing: 110] [Article Influence: 23.0] [Reference Citation Analysis]
57 Ushiroda C, Naito Y, Takagi T, Uchiyama K, Mizushima K, Higashimura Y, Yasukawa Z, Okubo T, Inoue R, Honda A, Matsuzaki Y, Itoh Y. Green tea polyphenol (epigallocatechin-3-gallate) improves gut dysbiosis and serum bile acids dysregulation in high-fat diet-fed mice. J Clin Biochem Nutr. 2019;65:34-46. [PMID: 31379412 DOI: 10.3164/jcbn.18-116] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 12.7] [Reference Citation Analysis]
58 Kordy K, Li F, Lee DJ, Kinchen JM, Jew MH, La Rocque ME, Zabih S, Saavedra M, Woodward C, Cunningham NJ, Tobin NH, Aldrovandi GM. Metabolomic Predictors of Non-alcoholic Steatohepatitis and Advanced Fibrosis in Children. Front Microbiol 2021;12:713234. [PMID: 34475864 DOI: 10.3389/fmicb.2021.713234] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Suárez M, Boqué N, Del Bas JM, Mayneris-Perxachs J, Arola L, Caimari A. Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease. Nutrients 2017;9:E1052. [PMID: 28937599 DOI: 10.3390/nu9101052] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 7.6] [Reference Citation Analysis]
60 Wu J, Li C, Bai L, Wu J, Bo R, Ye M, Huang L, Chen H, Rui W. Structural differences of polysaccharides from Astragalus before and after honey processing and their effects on colitis mice. Int J Biol Macromol 2021;182:815-24. [PMID: 33857512 DOI: 10.1016/j.ijbiomac.2021.04.055] [Reference Citation Analysis]
61 Noureddin M, Sanyal AJ. Pathogenesis of NASH: The Impact of Multiple Pathways. Curr Hepatol Rep 2018;17:350-60. [PMID: 31380156 DOI: 10.1007/s11901-018-0425-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
62 Zhu B, Chan SL, Li J, Li K, Wu H, Cui K, Chen H. Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment. Front Cardiovasc Med 2021;8:742382. [PMID: 34557535 DOI: 10.3389/fcvm.2021.742382] [Reference Citation Analysis]
63 Mukherjee S. Advances in the treatment of nonalcoholic steatohepatitis. World J Pharmacol 2020; 9(1): 1-12 [DOI: 10.5497/wjp.v9.i1.1] [Reference Citation Analysis]
64 Wilson CL, Mann DA, Borthwick LA. Epigenetic reprogramming in liver fibrosis and cancer. Adv Drug Deliv Rev. 2017;121:124-132. [PMID: 29079534 DOI: 10.1016/j.addr.2017.10.011] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
65 Riedl RA, Atkinson SN, Burnett CML, Grobe JL, Kirby JR. The Gut Microbiome, Energy Homeostasis, and Implications for Hypertension. Curr Hypertens Rep 2017;19:27. [PMID: 28316052 DOI: 10.1007/s11906-017-0721-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
66 Feng W, Wang H, Zhang P, Gao C, Tao J, Ge Z, Zhu D, Bi Y. Modulation of gut microbiota contributes to curcumin-mediated attenuation of hepatic steatosis in rats. Biochim Biophys Acta Gen Subj 2017;1861:1801-12. [PMID: 28341485 DOI: 10.1016/j.bbagen.2017.03.017] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 10.8] [Reference Citation Analysis]
67 Krautkramer KA, Dhillon RS, Denu JM, Carey HV. Metabolic programming of the epigenome: host and gut microbial metabolite interactions with host chromatin. Transl Res 2017;189:30-50. [PMID: 28919341 DOI: 10.1016/j.trsl.2017.08.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
68 Zhang Y, Tang K, Deng Y, Chen R, Liang S, Xie H, He Y, Chen Y, Yang Q. Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced NAFLD rats. Biomed Pharmacother. 2018;102:1025-1036. [PMID: 29710519 DOI: 10.1016/j.biopha.2018.03.158] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 10.3] [Reference Citation Analysis]
69 Shen Z, Liu XD, Zhao XF. Silencing FoxO1 expression promotes expression of high molecular weight adiponectin in 3T3-L1 cells. Shijie Huaren Xiaohua Zazhi 2017; 25(1): 56-63 [DOI: 10.11569/wcjd.v25.i1.56] [Reference Citation Analysis]
70 Liu Y, Xie C, Zhai Z, Deng ZY, De Jonge HR, Wu X, Ruan Z. Uridine attenuates obesity, ameliorates hepatic lipid accumulation and modifies the gut microbiota composition in mice fed with a high-fat diet. Food Funct 2021;12:1829-40. [PMID: 33527946 DOI: 10.1039/d0fo02533j] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Jian C, Luukkonen P, Sädevirta S, Yki-Järvinen H, Salonen A. Impact of short-term overfeeding of saturated or unsaturated fat or sugars on the gut microbiota in relation to liver fat in obese and overweight adults. Clin Nutr 2021;40:207-16. [PMID: 32536582 DOI: 10.1016/j.clnu.2020.05.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
72 Ahmed LA, Salem MB, Seif El-Din SH, El-Lakkany NM, Ahmed HO, Nasr SM, Hammam OA, Botros SS, Saleh S. Gut microbiota modulation as a promising therapy with metformin in rats with non-alcoholic steatohepatitis: Role of LPS/TLR4 and autophagy pathways. Eur J Pharmacol 2020;887:173461. [PMID: 32758573 DOI: 10.1016/j.ejphar.2020.173461] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
73 Nakashima A, Sugimoto R, Suzuki K, Shirakata Y, Hashiguchi T, Yoshida C, Nakano Y. Anti-fibrotic activity of Euglena gracilis and paramylon in a mouse model of non-alcoholic steatohepatitis. Food Sci Nutr 2019;7:139-47. [PMID: 30680167 DOI: 10.1002/fsn3.828] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
74 Jahn D, Kircher S, Hermanns HM, Geier A. Animal models of NAFLD from a hepatologist's point of view. Biochim Biophys Acta Mol Basis Dis 2019;1865:943-53. [PMID: 29990551 DOI: 10.1016/j.bbadis.2018.06.023] [Cited by in Crossref: 32] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
75 Wan S, Huang C, Wang A, Zhu X. Ursolic acid improves the bacterial community mapping of the intestinal tract in liver fibrosis mice. PeerJ 2020;8:e9050. [PMID: 32355580 DOI: 10.7717/peerj.9050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Juanola O, Ferrusquía-Acosta J, García-Villalba R, Zapater P, Magaz M, Marín A, Olivas P, Baiges A, Bellot P, Turon F, Hernández-Gea V, González-Navajas JM, Tomás-Barberán FA, García-Pagán JC, Francés R. Circulating levels of butyrate are inversely related to portal hypertension, endotoxemia, and systemic inflammation in patients with cirrhosis. FASEB J 2019;33:11595-605. [PMID: 31345057 DOI: 10.1096/fj.201901327R] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 7.7] [Reference Citation Analysis]
77 Lang T, Zou S, Huang K, Guo M, Liu X, He X. Safety assessment of transgenic canola RF3 with bar and barstar gene on Sprague-Dawley (SD) rats by 90-day feeding test. Regulatory Toxicology and Pharmacology 2017;91:226-34. [DOI: 10.1016/j.yrtph.2017.10.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
78 Lei Y, Tang L, Liu S, Hu S, Wu L, Liu Y, Yang M, Huang S, Tang X, Tang T, Zhao X, Vlodavsky I, Zeng S, Tang B, Yang S. Parabacteroides produces acetate to alleviate heparanase-exacerbated acute pancreatitis through reducing neutrophil infiltration. Microbiome 2021;9:115. [PMID: 34016163 DOI: 10.1186/s40168-021-01065-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Cremonini E, Wang Z, Bettaieb A, Adamo AM, Daveri E, Mills DA, Kalanetra KM, Haj FG, Karakas S, Oteiza PI. (-)-Epicatechin protects the intestinal barrier from high fat diet-induced permeabilization: Implications for steatosis and insulin resistance. Redox Biol 2018;14:588-99. [PMID: 29154190 DOI: 10.1016/j.redox.2017.11.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 11.6] [Reference Citation Analysis]
80 Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab 2021;50:101122. [PMID: 33220492 DOI: 10.1016/j.molmet.2020.101122] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
81 Bakhshimoghaddam F, Alizadeh M. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms. Clin Nutr ESPEN 2021;44:61-8. [PMID: 34330514 DOI: 10.1016/j.clnesp.2021.05.012] [Reference Citation Analysis]
82 Shen SH, Zhong TY, Peng C, Fang J, Lv B. Structural modulation of gut microbiota during alleviation of non-alcoholic fatty liver disease with Gynostemma pentaphyllum in rats. BMC Complement Med Ther 2020;20:34. [PMID: 32024509 DOI: 10.1186/s12906-020-2835-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
83 Wang R, Li H, Yang X, Xue X, Deng L, Shen J, Zhang M, Zhao L, Zhang C. Genetically Obese Human Gut Microbiota Induces Liver Steatosis in Germ-Free Mice Fed on Normal Diet. Front Microbiol 2018;9:1602. [PMID: 30079055 DOI: 10.3389/fmicb.2018.01602] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
84 Mukherji A, Bailey SM, Staels B, Baumert TF. The circadian clock and liver function in health and disease. Journal of Hepatology 2019;71:200-11. [DOI: 10.1016/j.jhep.2019.03.020] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 15.0] [Reference Citation Analysis]
85 Ren SM, Zhang QZ, Chen ML, Jiang M, Zhou Y, Xu XJ, Wang DM, Pan YN, Liu XQ. Anti-NAFLD effect of defatted walnut powder extract in high fat diet-induced C57BL/6 mice by modulating the gut microbiota. J Ethnopharmacol 2021;270:113814. [PMID: 33444725 DOI: 10.1016/j.jep.2021.113814] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
86 Jang HR, Park HJ, Kang D, Chung H, Nam MH, Lee Y, Park JH, Lee HY. A protective mechanism of probiotic Lactobacillus against hepatic steatosis via reducing host intestinal fatty acid absorption. Exp Mol Med 2019;51:1-14. [PMID: 31409765 DOI: 10.1038/s12276-019-0293-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
87 Liang S, Zhang Y, Deng Y, He Y, Liang Y, Liang Z, Chen Y, Tang K, Chen R, Yang Q. The Potential Effect of Chinese Herbal Formula Hongqijiangzhi Fang in Improving NAFLD: Focusing on NLRP3 Inflammasome and Gut Microbiota. Evid Based Complement Alternat Med 2018;2018:5378961. [PMID: 29675053 DOI: 10.1155/2018/5378961] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
88 Vallianou N, Christodoulatos GS, Karampela I, Tsilingiris D, Magkos F, Stratigou T, Kounatidis D, Dalamaga M. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. Biomolecules 2022;12:56. [DOI: 10.3390/biom12010056] [Reference Citation Analysis]
89 Aragonès G, González-García S, Aguilar C, Richart C, Auguet T. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease. Biomed Res Int 2019;2019:8507583. [PMID: 30719448 DOI: 10.1155/2019/8507583] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
90 Sherf-dagan S, Zelber-sagi S, Zilberman-schapira G, Webb M, Buch A, Keidar A, Raziel A, Sakran N, Goitein D, Goldenberg N, Mahdi JA, Pevsner-fischer M, Zmora N, Dori-bachash M, Segal E, Elinav E, Shibolet O. Probiotics administration following sleeve gastrectomy surgery: a randomized double-blind trial. Int J Obes 2018;42:147-55. [DOI: 10.1038/ijo.2017.210] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
91 Armutcu F. Organ crosstalk: the potent roles of inflammation and fibrotic changes in the course of organ interactions. Inflamm Res 2019;68:825-39. [PMID: 31327029 DOI: 10.1007/s00011-019-01271-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
92 Chen B, Zheng YM, Zhang MQ, Han Y, Zhang JP, Hu CQ. Microarray Expression Profiling and Raman Spectroscopy Reveal Anti-Fatty Liver Action of Berberine in a Diet-Induced Larval Zebrafish Model. Front Pharmacol 2019;10:1504. [PMID: 31969822 DOI: 10.3389/fphar.2019.01504] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
93 He X, Qi Z, Hou H, Qian L, Gao J, Zhang X. Structural and functional alterations of gut microbiome in mice induced by chronic cadmium exposure. Chemosphere 2020;246:125747. [DOI: 10.1016/j.chemosphere.2019.125747] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
94 Ma S, Jiang Y, Zhang B, Pang J, Xu X, Sun J, Lv X, Cai Q. Comparison of the Modulatory Effect on Intestinal Microbiota between Raw and Bran-Fried Atractylodis Rhizoma in the Rat Model of Spleen-Deficiency Syndrome. Int J Environ Res Public Health 2019;16:E3183. [PMID: 31480462 DOI: 10.3390/ijerph16173183] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
95 Janssen AWF, Houben T, Katiraei S, Dijk W, Boutens L, van der Bolt N, Wang Z, Brown JM, Hazen SL, Mandard S, Shiri-Sverdlov R, Kuipers F, Willems van Dijk K, Vervoort J, Stienstra R, Hooiveld GJEJ, Kersten S. Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: a potential role for bile acids. J Lipid Res. 2017;58:1399-1416. [PMID: 28533304 DOI: 10.1194/jlr.m075713] [Cited by in Crossref: 56] [Cited by in F6Publishing: 35] [Article Influence: 11.2] [Reference Citation Analysis]
96 Anania C, Perla FM, Olivero F, Pacifico L, Chiesa C. Mediterranean diet and nonalcoholic fatty liver disease. World J Gastroenterol 2018; 24(19): 2083-2094 [PMID: 29785077 DOI: 10.3748/wjg.v24.i19.2083] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 51] [Article Influence: 14.3] [Reference Citation Analysis]
97 Liu Q, Niu CY. From "two hit theory" to "multiple hit theory": Implications of evolution of pathogenesis concepts for treatment of non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2019; 27(19): 1171-1178 [DOI: 10.11569/wcjd.v27.i19.1171] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
98 Sun WL, Yang JW, Dou HY, Li GQ, Li XY, Shen L, Ji HF. Anti-inflammatory effect of luteolin is related to the changes in the gut microbiota and contributes to preventing the progression from simple steatosis to nonalcoholic steatohepatitis. Bioorg Chem 2021;112:104966. [PMID: 33991837 DOI: 10.1016/j.bioorg.2021.104966] [Reference Citation Analysis]
99 Sun WL, Li XY, Dou HY, Wang XD, Li JD, Shen L, Ji HF. Myricetin supplementation decreases hepatic lipid synthesis and inflammation by modulating gut microbiota. Cell Rep 2021;36:109641. [PMID: 34469716 DOI: 10.1016/j.celrep.2021.109641] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Wei Z, Liu N, Tantai X, Xing X, Xiao C, Chen L, Wang J. The effects of curcumin on the metabolic parameters of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Hepatol Int 2019;13:302-13. [DOI: 10.1007/s12072-018-9910-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
101 Qiu L, Guo C. Natural Aldose Reductase Inhibitor: A Potential Therapeutic Agent for Non-alcoholic Fatty Liver Disease. Curr Drug Targets 2020;21:599-609. [PMID: 31589122 DOI: 10.2174/1389450120666191007111712] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
102 Hughes A, Dahmus J, Rivas G, Hummer B, Chen See JR, Wright JR, Lamendella R, Schmitz KH, Sciamanna C, Ruffin M, Patterson AD, Loomba R, Stine JG. Exercise Training Reverses Gut Dysbiosis in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis: A Proof of Concept Study. Clin Gastroenterol Hepatol 2021;19:1723-5. [PMID: 32882426 DOI: 10.1016/j.cgh.2020.08.063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
103 Elolimy A, Alharthi A, Zeineldin M, Parys C, Helmbrecht A, Loor JJ. Supply of Methionine During Late-Pregnancy Alters Fecal Microbiota and Metabolome in Neonatal Dairy Calves Without Changes in Daily Feed Intake. Front Microbiol 2019;10:2159. [PMID: 31608024 DOI: 10.3389/fmicb.2019.02159] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
104 Kutlu O, Kaleli HN, Ozer E. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2018;2018:8543763. [PMID: 30228976 DOI: 10.1155/2018/8543763] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 8.0] [Reference Citation Analysis]
105 Dornas W, Lagente V. Intestinally derived bacterial products stimulate development of nonalcoholic steatohepatitis. Pharmacol Res. 2019;141:418-428. [PMID: 30658094 DOI: 10.1016/j.phrs.2019.01.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
106 Zhou Z, Kim JW, Qi J, Eo SK, Lim CW, Kim B. Toll-Like Receptor 5 Signaling Ameliorates Liver Fibrosis by Inducing Interferon β-Modulated IL-1 Receptor Antagonist in Mice. Am J Pathol 2020;190:614-29. [PMID: 31972159 DOI: 10.1016/j.ajpath.2019.11.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
107 Tang C, Ding R, Sun J, Liu J, Kan J, Jin C. The impacts of natural polysaccharides on intestinal microbiota and immune responses – a review. Food Funct 2019;10:2290-312. [DOI: 10.1039/c8fo01946k] [Cited by in Crossref: 56] [Cited by in F6Publishing: 19] [Article Influence: 18.7] [Reference Citation Analysis]
108 Xu P, Hong F, Wang J, Wang J, Zhao X, Wang S, Xue T, Xu J, Zheng X, Zhai Y. DBZ is a putative PPARγ agonist that prevents high fat diet-induced obesity, insulin resistance and gut dysbiosis. Biochim Biophys Acta Gen Subj 2017;1861:2690-701. [PMID: 28736228 DOI: 10.1016/j.bbagen.2017.07.013] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
109 Schwenger KJP, Bolzon CM, Li C, Allard JP. Non-alcoholic fatty liver disease and obesity: the role of the gut bacteria. Eur J Nutr 2019;58:1771-84. [PMID: 30306296 DOI: 10.1007/s00394-018-1844-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
110 Svegliati-Baroni G, Patrício B, Lioci G, Macedo MP, Gastaldelli A. Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH. Int J Mol Sci 2020;21:E5820. [PMID: 32823659 DOI: 10.3390/ijms21165820] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
111 Yang M, Geng CA, Liu X, Guan M. Lipid Disorders in NAFLD and Chronic Kidney Disease. Biomedicines 2021;9:1405. [PMID: 34680522 DOI: 10.3390/biomedicines9101405] [Reference Citation Analysis]
112 Rockstroh JK. Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in HIV. Curr HIV/AIDS Rep 2017;14:47-53. [PMID: 28284005 DOI: 10.1007/s11904-017-0351-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
113 Kiouptsi K, Reinhardt C. Contribution of the commensal microbiota to atherosclerosis and arterial thrombosis. Br J Pharmacol 2018;175:4439-49. [PMID: 30129122 DOI: 10.1111/bph.14483] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
114 Tang C, Meng F, Pang X, Chen M, Zhou L, Lu Z, Lu Y. Protective effects of Lactobacillus acidophilus NX2-6 against oleic acid-induced steatosis, mitochondrial dysfunction, endoplasmic reticulum stress and inflammatory responses. Journal of Functional Foods 2020;74:104206. [DOI: 10.1016/j.jff.2020.104206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]